HPV Vaccine for HPV Prevention
Trial Summary
What is the purpose of this trial?
Human papillomavirus (HPV) is a common sexually-transmitted virus which causes infections that usually last only a few months, but sometimes can last a long time and cause cancers of the cervix, vagina, vulva, anus or oropharynx over many years among adults. This phase IIA trial studies how well does the nonavalent HPV vaccine (which can prevent nine different types of HPV) work when given in an alternative dosing schedule to heathy young research participants.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot participate if you are on immunosuppressive drugs, chemotherapy, or certain other treatments. It's best to discuss your specific medications with the trial team.
What data supports the effectiveness of the HPV vaccine treatment for HPV prevention?
Is the HPV vaccine safe for humans?
The HPV vaccines, including the nonavalent version, have been studied extensively for safety. Most studies show they are generally safe, but some trials reported more severe adverse events in the vaccine group compared to control groups. However, these events were not judged to be directly related to the vaccine.678910
How is the nonavalent HPV vaccine different from other HPV vaccines?
Research Team
Hsiao-Hui (Sherry) Chow
Principal Investigator
The University of Arizona Medical Center-University Campus
Eligibility Criteria
This trial is for healthy, medically well boys and girls who can understand and agree to participate. They must not have had an HPV vaccine before, be on immunosuppressive drugs, or have significant health issues like heart or kidney problems. Pregnant individuals or those with a history of allergic reactions to similar vaccines are excluded.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Priming Injection
Participants receive the recombinant human papillomavirus nonavalent vaccine intramuscularly at baseline
Booster Injection
Participants receive booster injections of the vaccine at 24 and 30 months
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Recombinant Human Papillomavirus Nonavalent Vaccine
Find a Clinic Near You
Who Is Running the Clinical Trial?
National Cancer Institute (NCI)
Lead Sponsor